Deals in Depth: August 2008
Executive Summary
August 2008 dealmaking highlights: excluding the $3.1 billion CSL/Talecris takeover, there was a weak showing in M&As across all industries in both the number of transactions done and total dollar value; and CSL's $1.5 billion private placement to support the acquisition was mainly responsible for the 75% showing in PIPE financings.
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.